IMPORTANCE Uveal melanoma (UM) is an intraocular primary malignant neoplasm that often gives rise to metastatic disease for which there are no effective therapies. A substantial proportion of UMs express the cancer-testis antigen PRAME (preferentially expressed antigen in melanoma), which can potentially be targeted by adoptive T-cell therapy.
U veal melanoma (UM) is a pigment cell-derived malignant neoplasm that occurs in the eye and can lead to metastases, usually affecting the liver. Several characteristics are associated with the development of metastases, such as large tumor size, the presence of epithelioid cells, the loss of 1 chromosome 3 and the presence of additional copies of chromosome 8q, 1,2 and a specific gene expression profile known as class 2. 3, 4 In addition, high-risk tumors are characterized by an inflammatory phenotype, with high numbers of infiltrating CD4 + and CD8 + T cells, macrophages, and increased expression of HLA class I and II. [5] [6] [7] [8] [9] Treatment options currently used to treat metastatic UM include liver-directed chemotherapy and systemic targeted and immune therapies. 10 However, these treatments have resulted in durable responses in very few patients. 11 The potential efficacy of immunotherapy has been limited, presumably owing to the small number of mutations leading to neoantigen expression in UM; immunotherapy with checkpoint inhibitors has shown very low response rates in metastatic UM.
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Another possible treatment option for patients with metastasized UM is targeted therapy with T cells directed against tumor-associated antigens. Recently, Field et al 15 reported that the cancer-testis antigen PRAME (preferentially expressed antigen of melanoma) is expressed in many primary UMs and is a marker for increased risk of metastasis in Class 1 and disomy 3 UMs. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. 16 Subsequently, it has been shown that PRAME (Ensembl: ENST00000398741.5) is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non-small cell lung cancer, and leukemia, 16 ,17 whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium. 16 Griffioen et al 18 have shown that PRAME-specific CD8 + T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. However, these T cells had a low avidity for PRAME-expressing tumor cells, and their T-cell receptors (TCRs) will therefore unlikely be useful for therapeutic applications. A previous study isolated PRAME-specific HLA-A2 restricted T-cell clones, which exhibited a high specificity and reactivity for PRAME, derived from a patient who underwent an HLA-A2 mismatched stem cell transplant.
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These PRAME-specific T cells were able to lyse multiple PRAME-positive malignant cell lines, including cell lines derived from cutaneous melanoma, lung cancer, breast cancer, and acute myeloid leukemia. It was demonstrated by TCR gene transfer that the high-affinity, PRAME-specific TCR could potentially be used for PRAME-TCR gene therapy.
A clinical trial to evaluate PRAME-TCR gene therapy is being initiated. To determine whether patients with metastatic UM may be potential candidates for PRAME-TCR gene therapy, we expanded our analysis to UM and tested whether PRAME is expressed in primary and metastatic UM and whether high-affinity, PRAME-specific T cells can recognize PRAMEexpressing UM cell lines. 
Methods

Study Population
DNA and Gene Expression Analysis
From 64 fresh-frozen specimens, DNA for single-nucleotide polymorphism and copy number analyses was extracted with the QIAmp DNA Mini kit (Qiagen). Single-nucleotide polymorphism analysis was performed with the Affymetrix 250K_NSP-chip and Affymetrix Cytoscan HD chip (Affymetrix) to assess aberrations in chromosomes 3 and 6. Information on the copy number of 8q was obtained by
Key Points
Question Is there a rationale for preferentially expressed antigen in melanoma (PRAME)-specific T-cell therapy for patients with metastatic uveal melanoma?
Findings This experimental cohort study found that PRAME is expressed in primary uveal melanoma and its metastases, as is HLA class I. Also, PRAME-specific T cells showed reactivity against PRAME-positive uveal melanoma cell lines.
Meaning For patients with metastatic uveal melanoma, the use of PRAME-specific T-cell therapy may be helpful.
droplet digital polymerase chain reaction. The RNA for gene expression profiling was isolated with the RNeasy mini Kit (Qiagen). PRAME RNA expression was measured on the Illumina HT-12v4 chip (Illumina) using probe ILMN_1700031.
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Expression data for disomy 3 UMs were included in a previous publication.
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Recognition of UM Cell Lines By PRAME-Specific T Cells 
HLA Class I Staining and Scoring
Immunofluorescence staining for expression of human HLA-A, HLA-B/C, and β2-microglobulin (β2M) was performed on paraffin-embedded samples of metastases as previously described, 28 and we used the scoring system of Ruiter et al 29 and other studies 30,31 (eAppendix in the Supplement).
Statistical Analysis
Statistical analysis was performed with SPSS, version 20.0.0 (IBM Corp). PRAME gene expression was dichotomized as negative and positive. Clinical, histopathologic, and genetic parameters were compared between both groups using the Pearson χ 2 test for categorical prognostic parameters and the Mann-Whitney U test for continuous prognostic parameters.
The Kaplan-Meier curve and log-rank test were used to perform disease-specific survival analysis for patients with primary UM with negative and positive PRAME expression. Death due to metastasis was considered an event. Patients who died owing to another cause or an unknown cause were censored.
Results
Distribution of PRAME Expression in Primary UM PRAME gene expression was analyzed in 64 primary UMs using an RNA expression microarray ( Figure 1A ). The mean (SD) age of the patients at enucleation was 60.6 (15.6) years, and 33 of the 64 patients (52%) were men. When expression values were plotted from lowest to highest, an inflection point in the slope was noted at the sample with expression of 7.23 Illumina units, so we took this point as the threshold for positive PRAME expression. Tumors with expression less than 7.23 Illumina units were categorized as PRAME-negative UM (n = 35), and those with expression of 7.23 Illumina units or more were categorized as PRAME-positive UM (n = 29).
We compared the clinical, histopathologic, and chromosome data between the 2 groups of patients with tumors ( Table 1) . Both groups did not differ in age or sex. PRAME expression was associated with prognostically poor tumor characteristics; PRAME-positive tumors had the largest median basal diameter (15.0 vs 12.0 mm; P = .005) and a more frequent involvement of the ciliary body (59% vs 26%; P = .008) compared with PRAME-negative tumors. Of the 29 PRAMEpositive tumors, 21 (72%) showed monosomy of chromosome 3, whereas this was the case in 20 (57%) of the 35 PRAMEnegative tumors (P = .21). PRAME expression correlated with amplification of chromosome 8q (66% vs 23%; P = .002). Tumors with chromosome 8q copies were categorized as follows: a copy number between 1.9 and 2.1 was categorized as normal, between 2.2 and 3.1 as gain, and more than 3.1 as amplification of chromosome 8q. When comparing the KaplanMeier survival curves, we found that patients with PRAMEpositive tumors had a shorter disease-specific survival than patients with PRAME-negative tumors (median survival, 47 vs 88 months; P = .02) ( Figure 1C ).
Recognizing UM Cell Lines by PRAME-Specific T-Cell Clones
Two previously identified PRAME-specific T-cell clones (HSS1 and HSS3) were used to determine whether UM cell lines can potentially be recognized by PRAME-specific T cells. 19 First, PRAME-dependent recognition of the PRAME-specific T-cell clones was demonstrated by introducing full-length PRAME into HLA-A2-positive cell line SW480. As demonstrated in Figure 2A , the PRAME-specific T-cell clones do not recognize the HLA-A2-negative, PRAME-negative SW480 cells. However, retroviral introduction of PRAME into SW480 resulted in efficient recognition, comparable to HLA-A2-positive, PRAME-positive LCL-JY and K562+A2. Before the UM cell lines were tested for recognition by the PRAME-specific T-cell clones, the HLA-A2 expression of the UM cell lines was measured by fluorescence-activated cell sorting analysis using specific antibodies directed against HLA class I (W632) and HLA-A2 (BB7.2). We confirmed that only UM cell line Mel290 was HLA-A2 positive. The remaining UM cell lines were HLA-A2 negative and were therefore retrovirally transduced with HLA-A*02:01. After retroviral transduction, all 7 UM cell lines were recognized by the USP11-specific T-cell clone HSS12, confirming that HLA-A*0201 was now expressed on all UM cell lines. The results shown in Figure 2B demonstrate that 4 of 7 UM cell lines were efficiently recognized by the PRAME-specific Tcell clones HSS1 and HSS3, as coincubation led to production of IFN-γ by both of the PRAME-specific T-cell clones. Using realtime quantitative polymerase chain reaction, we confirmed that the 4 UM cell lines recognized by the PRAME-specific T-cell clones expressed PRAME ( Figure 2C ). These data demonstrate that PRAME-positive UM cell lines can be recognized by PRAME-specific T cells and that the recognition potential of the T cells correlated with PRAME expression in these cell lines.
PRAME Expression in UM Metastases
Next, we analyzed PRAME expression in 16 UM metastatic samples using an mRNA FISH assay to stain PRAME mRNA in FFPE tissue sections. We validated this technique on primary UM with known PRAME expression levels. Two consecutive FFPE tissue sections from 14 primary tumors were hybridized with both GAPDH (Ensembl: ENST00000229239.9) and PRAME in a dye-mirrored way. One section of each tumor was stained using the GAPDH probe set labeled with the dye Quasar 570 together with the PRAME probe set labeled with Quasar 670, while the other section was stained with the same probe sets but labeled the other way around. The presence of PRAME was determined as described in the eAppendix in the Supplement by 2 independent observers (M.H.M.H. and S.J.L.), with a κ score of 0.857 ( Figure 1B ). All tumors that were PRAME negative according to the Illumina data (<7.23) were also scored as PRAME negative by the mRNA FISH technique. All tumors with a PRAME expression level greater than 10 according to the Illumina data were scored positive by the mRNA FISH technique. We subsequently tested PRAME by mRNA FISH in metastases from 16 patients with UM. GAPDH but not PRAME expression was seen in tumors from 5 patients, whereas GAPDH as well as PRAME expression was present in metastases from 11 patients. An example of negative and positive PRAME expression by mRNA FISH is shown in Figure 3 . In 2 patients, multiple metastases were available (2 in 1 patient and 4 in the second patient), and PRAME expression was identical between the different metastases of each patient. The results of all patients together demonstrate expression of PRAME in metastatic UM in 11 of 16 patients.
HLA Class I Expression in UM Metastases
For TCR-mediated immunotherapeutic approaches, target antigens are recognized in the context of HLA class I molecules. It is therefore essential that not only PRAME but also HLA class I is expressed on UM metastases to induce a potent immune reactivity of TCR-modified, PRAME-specific T cells. We therefore analyzed HLA class I expression by triple immunofluorescence HLA class I staining on the FFPE tissue sections of the 16 patients with UM metastases. When multiple metastases from a single patient were available, HLA class I expression patterns were similar between different metastases. For 10 of the 16 patients with UM metastases, expression of HLA-A and HLA-B/C, as well as β2M expression, was high and homo- Follow-up, mo No. at risk PRAME negative PRAME positive PRAME negative PRAME positive A, PRAME expression determined using 2 different probes in 64 cases of UM using an Illumina HT-12v4 microarray. Using probe ILMN_1700031, tumors are dichotomized into negative and positive. The samples on the right of the arrow are categorized as positive PRAME expression and the samples on the left of the arrow are categorized as negative PRAME expression. B, Illumina expression data and messenger RNA (mRNA) fluorescence in situ hybridization (FISH) scoring for 14 primary UMs demonstrating specificity and sensitivity of the PRAME probe sets. The κ value for mRNA FISH between both observers was 0.857. Plus sign indicates positive expression; minus sign, negative expression. C, Survival curve of patients with negative and positive PRAME-expressing primary UM.
geneous. In 2 patients, the staining for HLA-A and HLA-B/C, as well as β2M, was weak but positive, whereas in 3 patients, expression of HLA-A and HLA-B/C, as well as of β2M, was negative. Overall, UM metastases from 10 of 16 patients (63%) demonstrated a high HLA class I expression.
As mentioned previously, PRAME expression was observed in 11 of 16 patients (69%). In 8 of the 16 patients, concomitant expression of PRAME and HLA class I was observed in the metastases, suggesting that half of metastatic UMs could be positive for both PRAME and HLA class I ( Table 2 ) and, therefore, can potentially be candidates for treatment with PRAME-TCR gene therapy.
Discussion
In the present study, we found that PRAME was expressed at the RNA level in 45% of primary UMs (29 of 64), and PRAME expression was associated with ciliary body involvement, largest basal diameter, and amplification of chromosome 8q. PRAME expression occurred in disomy 3 as well as in monosomy 3 tumors, which confirms the findings reported by Field et al. 32 Among all primary UMs, PRAME expression was associated with a poorer disease-specific survival.
We have demonstrated that the high-affinity, PRAMEspecific T cells are able to efficiently recognize PRAMEpositive UM cell lines. Furthermore, we demonstrated that 50% of the 16 patients with UM have metastases that express both PRAME and HLA class I. In 2 patients from whom multiple metastases were available, we were able to demonstrate that PRAME expression was identical between the different metastases of each patient. PRAME-TCR-specific T-cell therapy is directed against all patients with metastatic UM with PRAME-positive metastases, irrespective of the size of the primary tumor. The PRAME-TCR-engineered T cells used in the upcoming gene therapy study to treat acute myeloid leukemia and metastatic sarcoma recognize and lyse tumor cells when PRAME is processed and presented on the tumor cell surface in the context of HLA-A*02:01. 19 Therefore, this gene therapy study will be available for all HLA-A*02:01-positive patients, which comprise 50% of the Western European and North American population. In patients with primary UM, the frequency of HLA-A*02:01 was also around 50%. 33 We are currently also searching for other high-affinity, PRAME-specific TCRs restricted to other HLA class I molecules to broaden the PRAME-TCR gene therapy options. If the clinical studies using this specific TCR demonstrate promising results, we will initiate clinical studies with these newly identified PRAME-TCRs. For patients with metastatic UM, we will perform a biopsy of the metastases and analyze whether PRAME is present to determine whether to treat them with PRAME-TCR gene therapy. Any effect of this treatment on the primary tumor is unlikely because most of these patients have already undergone enucleation or radiation, and therefore less or no primary tissue should remain. The advantage of PRAME-TCR gene therapy is that a broad group of patients with different malignant neoplasms can be treated with this TCR therapy as long as the patient is HLA-A2 positive and the tumor expresses PRAME. The PRAMEspecific T cells, however, may exhibit some reactivity against mature dendritic cells and kidney epithelial cells, which express PRAME at a lower level. 19 This reactivity could lead to Interferon γ, pg/mL Confirmation of PRAME specificity and HLA-A2 restriction of PRAME-specific T-cell clones of HSS1 and HSS3
A PRAME-specific T-cell clones stimulated with UM cell lines
B
Expression of PRAME mRNA 
Rel Exp
A, PRAME-specific T-cell clones HSS1 and HSS3 were stimulated with the PRAME-negative HLA-A2-positive cell line SW480, SW480 retrovirally transduced with PRAME (SW480+PRAME), HLA-A2-positive LCL-JY cell line expressing low levels of PRAME, and HLA-A2 transduced K562 cell line (K562+A2). B, PRAME-specific T-cell clones HSS1 and HSS3 were stimulated with different UM cell lines. Uveal melanoma cell lines negative for HLA-A2 were retrovirally transduced with HLA-A2 (+ A2). Clone pp65-A2 recognizes a peptide of pp65 in the context of HLA-A2 and serves as a negative control. Clone HSS12 is reactive against the household gene USP11, and was used to confirm that the UM cell lines are HLA-A2 positive. Interferon γ production was measured after 18 hours of co-culture by standard enzyme-linked immunosorbent assay. Experiments were carried out in duplicate. C, The expression of PRAME messenger RNA (mRNA) in different cells was measured by real-time quantitative polymerase chain reaction and is shown as fold expression of the PRAME-positive cutaneous melanoma cell line Mel1.14, which was set to 1. Rel Exp indicates relative expression of PRAME.
nephrotoxicity and long-term depletion of mature dendritic cells when the PRAME-TCR therapy is applied in a clinical setting. Therefore, the PRAME-TCR-engineered T cells will be equipped with the suicide switch iCasp9 to eliminate reactive T cells in case of adverse effects. Successful elimination of iCasp9-transduced T cells has been reported in patients with graft-vs-host disease after a haploidentical stem cell transplant, leading to resolution of the graft-vs-host disease by elimi- A, PRAME mRNA expression of PRAME-positive UM metastasis; PRAME mRNA is shown as small white speckles (arrowheads). B, GAPDH mRNA expression of UM metastasis shown in A; GAPDH mRNA is shown as small white speckles (arrowheads). C, Merged images with 4′,6-diamidino-2-phenylindole dilactate (DAPI) (blue) of A and B; PRAME is shown in small green dots and GAPDH in small red dots. D, PRAME-negative UM metastasis. E, GAPDH mRNA expression of UM metastasis shown in D; GAPDH mRNA is shown as small white speckles (arrowheads). F, Merged images with DAPI (blue) of D and E. GAPDH is shown in small red dots. Abbreviations: β2M, β2-microglobulin; FISH, fluorescence in situ hybridization; mRNA, messenger RNA; UM, uveal melanoma.
a The staining intensity scoring system is described in the eAppendix in the Supplement. 
PRAME as a Target for Immunotherapy in Metastatic Uveal
Limitations
This study has several limitations. First, we tested PRAME expression in a small cohort of patients with UM metastases because no other adequate FFPE tissues were available. However, we were still able to detect PRAME in 11 of 16 samples and in 8 of 16 patients together with HLA class I, thereby showing that concomitant expression of PRAME and HLA class I is present in UM metastases. Second, 2 of the 4 tumors with intermediate PRAME values (7.23-8.13) were positive with mRNA FISH, and the other 2 were scored negative ( Figure 1B) , thereby showing that the sensitivity of our PRAME probes might not be high enough to demonstrate PRAME gene expression at low levels with 100% sensitivity. The detection of PRAME might be degraded in these tissues because we used FFPE samples. Most important, however, no tumors with a negative expression in the microarray were scored by the mRNA FISH as PRAME positive, thereby providing high specificity.
Conclusions
We found that 45% of the tested primary UMs express PRAME and that PRAME expression in these patients is associated with known risk factors for metastasis and with poorer overall survival. We found that 50% of the analyzed UM metastases expressed both PRAME and HLA class I and that highaffinity, PRAME-specific T cells were efficiently recognizing UM cell lines expressing PRAME. These findings provide supportive evidence for including patients with metastatic UM in clinical trials using PRAME-TCR gene therapy. was run in triplicate using cDNA from 20ng of total RNA. Relative mRNA expression of PRAME in samples was calculated using the 2 -CT method 1 with the expression of PBGD serving as endogenous reference gene and the average expression of PRAME in Mel1.14 serving as calibrator.
PRAME Expression by mRNA Fluorescence in situ Hybridization
An oligonucleotide probe for PRAME mRNA was designed using the Stellaris ®FISH Probe Designer (Biosearch technologies Inc., Petaluma, CA, USA). All probes were individually analyzed and probes that contained less than two mismatched bases with any non-PRAME mRNA molecule were removed. A total of 46 probes was selected.
Oligonucleotide probes recognizing GAPDH were commercially available from BioSearch Technologies (Petaluma, CA, USA). For both genes, two probe sets were ordered: one labelled with the Quasar 570 fluorescent dye and one with the Quasar 670 fluorescent dye. In all experiments, GAPDH served as an internal control for mRNA quality of the FFPE slides. There was no spectral overlap between Quasar 570 and 670 probe sets.
To validate our PRAME probe sets, mRNA FISH was performed on FFPE slides from 14 of 64 primary UM of which we had RNA expression data available on the Illumina HT12v4 platform. Then, PRAME expression in UM metastases from 16 unrelated patients was assessed by mRNA FISH. Hybridizations were performed according to the each. Post-hybridization washes were done in 2X SSC with 10% formamide at 37°C, subsequent washing in 2X SSC to remove formamide and dehydration. Tissue sections were then embedded using ProLong® Gold (Thermo Fisher Scientific, Waltham, MA, USA) with DAPI (4',6-Diamidino-2-Phenylindole Dilactate). Pictures were taken using a Leica DM5500 microscope equipped with a 63X oil immersion lens with a numerical aperture of 1.4, using appropriate filter sets and in-house capturing software.
